Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
AstraZeneca
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Genmab
National Institutes of Health Clinical Center (CC)
Eikon Therapeutics
University of Miami
Seagen Inc.
Tizona Therapeutics, Inc
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Virginia Commonwealth University
Eli Lilly and Company
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Tempest Therapeutics
Merck Sharp & Dohme LLC
NuCana plc
Eisai Inc.
Yale University
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Yonsei University